Image: Shutterstock
February 6, 2024 07:28 AM ESTUpdated 10:40 AM
Pharma

Lil­ly's weight loss drug Zep­bound gen­er­ates $175M with­in weeks as Moun­jaro sales al­so soar

Katherine Lewin

News Reporter

Eli Lil­ly’s weight loss drug Zep­bound has pulled in $175.8 mil­lion in rev­enue since its ap­proval in No­vem­ber, the In­di­anapo­lis phar­ma said Tues­day in its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times